ANV419 EINZELSUBSTANZ ERSTE STUDIE AM MENSCHEN PHASE 1: EINE OFFENE, 5DOSIS-STEIGERUNGSSTUDIE BEI PATIENTEN MIT REZIDIVIERTEN/REFRAKTÄREN 6FORTGESCHRITTENEN SOLIDEN TUMOREN UND MULTIPLEM MYELOM.

Exclusion criteria (Data source: BASEC)

1.Symptomatic central nervous system (CNS) metastases. Definitely treated CNS metastases (e.g.,radiotherapy) stable for at least 6 weeks prior to Day 1 of study drug administration are acceptable.
2.Participants with an active second malignancy. Patients with precancerous lesions, concomitant early stages of prostate or breast cancer not requiring active treatment (past conditions currently resolved > 3 years prior to Screening are also acceptable), and squamous cell carcinoma of the skin not requiring systemic treatment are acceptable.
3.Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results, including uncontrolled diabetesmellitus, history of relevant pulmonary disorders(e.g.,severe bronchospasm, obstructive pulmonary disease), hyperthyroidismdue to thyroiditis and known autoimmune diseases or other disease with ongoing fibrosis. Stable vitiligo, autoimmune thyroiditis,and preexisting treated type 1 diabetes are acceptable and are not exclusion criteria.